Pharmacologic resistance in colorectal cancer: A review

William A. Hammond, Abhisek Swaika, K. A B I R Mody

Research output: Contribution to journalReview article

102 Citations (Scopus)

Abstract

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

Original languageEnglish (US)
Pages (from-to)57-84
Number of pages28
JournalTherapeutic Advances in Medical Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Colorectal Neoplasms
Therapeutics
PubMed
Neoplasms
Drug Therapy

Keywords

  • colon adenocarcinoma
  • colon cancer
  • resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacologic resistance in colorectal cancer : A review. / Hammond, William A.; Swaika, Abhisek; Mody, K. A B I R.

In: Therapeutic Advances in Medical Oncology, Vol. 8, No. 1, 01.01.2016, p. 57-84.

Research output: Contribution to journalReview article

Hammond, William A. ; Swaika, Abhisek ; Mody, K. A B I R. / Pharmacologic resistance in colorectal cancer : A review. In: Therapeutic Advances in Medical Oncology. 2016 ; Vol. 8, No. 1. pp. 57-84.
@article{86b6ab7b50ca4079961c24fc72f92a7b,
title = "Pharmacologic resistance in colorectal cancer: A review",
abstract = "Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.",
keywords = "colon adenocarcinoma, colon cancer, resistance",
author = "Hammond, {William A.} and Abhisek Swaika and Mody, {K. A B I R}",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1758834015614530",
language = "English (US)",
volume = "8",
pages = "57--84",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacologic resistance in colorectal cancer

T2 - A review

AU - Hammond, William A.

AU - Swaika, Abhisek

AU - Mody, K. A B I R

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

AB - Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

KW - colon adenocarcinoma

KW - colon cancer

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=84951827874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951827874&partnerID=8YFLogxK

U2 - 10.1177/1758834015614530

DO - 10.1177/1758834015614530

M3 - Review article

AN - SCOPUS:84951827874

VL - 8

SP - 57

EP - 84

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 1

ER -